NASDAQ : LXEO
Lexeo Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 3.06 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 251.05M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 257.61M |
| Enterprise Value | 52.72M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 82.04M |
| Shares Outstanding | 82.04M |
| Shares Change (YoY) | +113.19% |
| Shares Change (QoQ) | +5.47% |
| Owned by Insiders (%) | 0.39% |
| Owned by Institutions (%) | 78.68% |
| Float | 51.21M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.05 |
| P/TBV Ratio | 1.10 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 13.89 |
| Quick Ratio | 13.57 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,302.97 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -46.76% |
| Return on Assets (ROA) | -27.59% |
| Return on Invested Capital (ROIC) | -30.56% |
| Return on Capital Employed (ROCE) | -39.76% |
| Weighted Average Cost of Capital (WACC) | 13.00% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.39M |
| Employee Count | 63 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.65 |
| 52-Week Price Change | -68.31% |
| 50-Day Moving Average | 3.75 |
| 200-Day Moving Average | 5.21 |
| Relative Strength Index (RSI) | 48.26 |
| Average Volume (20 Days) | 1,445,623 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 17.55M |
| Short Previous Month | 19.25M |
| Short % of Shares Out | 21.40% |
| Short % of Float | 34.27% |
| Short Ratio (days to cover) | 9.16 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | -66.64M |
| Operating Income | -95.12M |
| Pretax Income | -87.27M |
| Net Income | -87.27M |
| EBITDA | -94.50M |
| EBIT | -95.12M |
| Earnings Per Share (EPS) | -$1.15 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 211.70M |
| Total Debt | 6.81M |
| Net Cash | 204.89M |
| Net Cash Per Share | $2.50 |
| Equity (Book Value) | 235.06M |
| Book Value Per Share | 2.99 |
| Working Capital | 202.22M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -88.37M |
| Capital Expenditures | -331,000 |
| Depreciation & Amortization | 613,000 |
| Net Borrowing | -515,000 |
| Free Cash Flow | -88.70M |
| FCF Per Share | -$1.08 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -113.19% |
| Shareholder Yield | n/a |
| Earnings Yield | -36.49% |
| FCF Yield | -34.43% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $20.30 |
| Price Target Difference | 546.50% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |